$BWB

Bridgewater Bancshares, Inc. Announces Second Quarter 2026 Financial Results

Bridgewater Bancshares Inc (BWB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bwb-20260721xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ Media Contact: Emily Karpenske | Senior Communication Specialist Emily.Karpenske@bwbmn.com | 952.653.0624 Investor Contact: Justin Horstman | VP Investor Relations Justin.Horstman@bwbmn.com | 952.542.5169 ​ July 21, 202

Original reporting
Published Jul 21, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 21, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BWB
Neutral
medium confidence
Mentioned
$BWB
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BWBNeutralMed
01

Why it matters

Investors will likely reprice the stock based on the combination of improved net interest margin and efficiency versus weaker asset quality metrics (nonperforming assets).

02

Market read

Fresh quarterly datapoints (NIM, net interest income, efficiency, nonperforming assets, CET1) provide a basis for near-term valuation and credit-risk reassessment.

03

What to watch

Core deposits declined QoQ while total deposits rose, which could affect funding stability and future NIM if the deposit mix continues to shift.

Relevance 7/10Novelty 7/10Timing: after-hours, following the July 21, 2026 8-K earnings release

Background

This is Bridgewater Bancshares’ SEC Form 8-K (Item 2.02) announcing second quarter 2026 financial results.

Company-level read

Ticker impact

$BWBNeutralMedium confidence
Context

Bridgewater Bancshares reported Q2 2026 net income of $14.0M, EPS $0.45, and net interest margin rising to 3.07% from 2.99% in Q1.

Expected impact

Near-term trading likely hinges on how investors weigh NIM/efficiency improvement versus the jump in nonperforming assets.

Evidence & confidence

The filing provides multiple directional datapoints: NIM +8 bps QoQ and efficiency ratio down, offset by nonperforming assets to total assets rising materially QoQ.

Market effects

Regional bank read-through: NIM expansion and deposit mix dynamics remain key, while rising nonperforming assets can pressure credit-sensitive sentiment.

Limited to the company’s footprint, but deposit and credit metrics can influence peers’ near-term sentiment.

Low; this is a single-bank earnings update with no stated macro or cross-border catalyst.

Counterpoint

The nonperforming assets spike may be transitional, while the company’s low annualized net charge-offs (0.04%) suggest credit losses are not yet accelerating.

Key entities

  • Bridgewater Bancshares, Inc.

    Parent company of Bridgewater Bank; reported Q2 2026 results and capital metrics in the 8-K.

  • Bridgewater Bank

    Operating bank referenced as the entity behind the parent’s results.

Related articles

$DALHighAI 8/10

Delta Air Lines (DAL) Reports Record Revenue but Cuts Earnings Guidance. Can Profits Recover?

Delta Air Lines (DAL) reported record Q3 revenue of $17.6B, up 15.7%, but cut 2026 EPS guidance to $5.10-$5.60 from $6.50-$7.50 due to rising fuel costs. Adjusted EPS of $1.72 missed estimates. Fuel expenses rose 62% to $4.1B, squeezing margins. Premium and loyalty revenue grew 18% each. The stock is up 20% in 6 months. Analysts maintain positive ratings but lower price targets.

$LEVIHighAI 8/10

Levi's CEO admits the company missed the biggest jeans trend of the year

Levi Strauss & Co. (LEVI) CEO Michelle Gass admitted the company missed the U.S. shift to low-rise jeans during the back-to-school season, impacting its direct-to-consumer sales. Despite a 4% revenue increase to $1.6 billion in Q3, shares fell nearly 5%. Levi's has since refocused marketing on low-rise styles and expects full-year revenue growth of about 6%.

$REGNMed

Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month

Regeneron (REGN) reported positive long-term results for its rare disease drug Pasatru, showing no new abnormal bone growth in an extended Phase 3 trial. The trial enrolled 63 adults, with zero new lesions in the Pasatru group compared to nine in the placebo group. REGN shares rose 2.8%, their best day in over a month. BofA raised its price target to $908, implying 19% upside. The company plans a new study for children and adolescents later this year.

$VLGEAMed

VLGEA Stock Falls 3% as Q4 Earnings Decline Y/Y Amid Rising Costs

Village Super Market (VLGEA) shares fell 3.1% after reporting Q4 FY2026 earnings. EPS declined 12.4% Y/Y to $0.92, while revenue rose 1.7% to $609.6M. Net income dropped 12.3% to $13.6M due to higher costs. Same-store sales grew 1.6%, with digital sales up 6%. Full-year sales increased 3.7% to $2.4B, but net income fell to $52.5M.